Evidence map›Paper›PMID 35893801›Full record

ArticlePharmaceutics2022

Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing.

Jan Macku, Katerina Kubova, Martina Urbanova, Jan Muselik, Ales Franc, Gabriela Koutna, Miroslava Pavelkova, David Vetchy, Josef Masek, Eliska Maskova and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jan MackuDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.
Katerina KubovaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.ORCID 0000-0002-4970-2084
Martina UrbanovaDepartment of NMR Spectroscopy, Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.
Jan MuselikDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.
Ales FrancDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.ORCID 0000-0002-2027-4717
Gabriela KoutnaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.
Miroslava PavelkovaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.
David VetchyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic.
Josef MasekDepartment of Pharmacology and Toxicology, Veterinary Research Institute, 621 00 Brno, Czech Republic.ORCID 0000-0001-6788-8487
Eliska MaskovaDepartment of Pharmacology and Toxicology, Veterinary Research Institute, 621 00 Brno, Czech Republic.
Jiri BrusDepartment of NMR Spectroscopy, Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.ORCID 0000-0003-2692-612X
Masaryk University · CZCzech Academy of Sciences, Institute of Macromolecular Chemistry · CZVeterinary Research Institute · CZ

Funding

Czech Science Foundation GA22-03187SMasaryk University MUNI/A/1251/2021
6 · The paper itself

Abstract

The growing need for processing natural lipophilic and often volatile substances such as thymol, a promising candidate for topical treatment of intestinal mucosa, led us to the utilization of solid-state nuclear magnetic resonance (ss-NMR) spectroscopy for the rational design of enteric pellets with a thymol self-emulsifying system (SES). The SES (triacylglycerol, Labrasol®, and propylene glycol) provided a stable o/w emulsion with particle size between 1 and 7 µm. The ex vivo experiment confirmed the SES mucosal permeation and thymol delivery to enterocytes. Pellets W90 (MCC, Neusilin®US2, chitosan) were prepared using distilled water (90 g) by the M1−M3 extrusion/spheronisation methods varying in steps number and/or cumulative time. The pellets (705−740 µm) showed mostly comparable properties—zero friability, low intraparticular porosity (0−0.71%), and relatively high density (1.43−1.45%). They exhibited similar thymol release for 6 h (burst effect in 15th min ca. 60%), but its content increased (30−39.6 mg/g) with a shorter process time. The M3-W90 fluid-bed coated pellets (Eudragit®L) prevented undesirable thymol release in stomach conditions (<10% for 3 h). A detailed, ss-NMR investigation revealed structural differences across samples prepared by M1−M3 methods concerning system stability and internal interactions. The suggested formulation and methodology are promising for other lipophilic volatiles in treating intestinal diseases.

Indexed as

ex vivo testingrational designself-emulsifying pelletsolid-state NMRstructurethymol

Identifiers

PMID35893801
PMCPMC9394426
OpenAlexW4287879382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.